Stephen Ahenkorah¹, Christopher Cawthorne², Erika Murce³, Christophe M Deroose⁴, Thomas Cardinaels⁵, Yann Seimbille³, Guy Bormans⁶, Maarten Ooms⁷, Frederik Cleeren⁸

Affiliations

¹NURA Research Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium; Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium.
²Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium.
³Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
⁴Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium; Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
⁵NURA Research Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium; Department of Chemistry, University of Leuven, Leuven, Belgium.
⁶Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium.
⁷NURA Research Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium.
⁸Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium. Electronic address: frederik.cleeren@kuleuven.be.

Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist

Direct comparison of [¹⁸F]AlF-NOTA-JR11 and [¹⁸F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist